Target Medicals

Target Medicals was established in 2012 with the aim of commercializing fundamental scientific achievements in the field of studying Cytochromes P450 - a superfamily of proteins (hemoproteins) represented in all classes of living organisms. The main result of the work was the launch of a project to develop an inhibitor of one of the Cytochromes of 450 people (11B2, aldosterone synthases).

History

2022: Attracting Investment

On February 1, 2022, it was announced that it was investing in Target Medicines. The Russian Direct Investment Fund (RDIF), the pharmaceutical giant AstraZeneca and Unicorn Capital Partners (the managing company of the PharmMed Innovation venture fund) invested in the developer of the drug for the treatment of hypertension.

According to the head of the RDIF, Kirill Dmitriev, these investments will help the startup test the drug and bring it to the world market in order to significantly improve the quality of life of millions of people.

RDIF invests in developer of drug for treatment of arterial hypertension "Target Medicals"

A promising development is an inhibitor of aldosterone synthase, an enzyme responsible for the production of aldosterone. Aldosterone is an essential component of the system involved in the regulation of circulating blood volume and blood pressure.

We are deeply impressed by the quality and competencies of the team, which managed to create a unique scientific development, without any exaggeration ahead of the world level. As far as we know, this is the first precedent of its kind when Big Pharma directly invests in the capital of a Russian biotech startup. As we hope, this will serve as a positive signal for the development of the entire Russian biomedical development segment, "said Alexei Vinogradov, Director General of Unicorn Capital Partners.

The appearance on the market of new drugs for the treatment of arterial hypertension is extremely important - by 2022 there are at least 1 billion people with this disease in the world.^[1]

Notes